Francque, Sven http://orcid.org/0000-0002-7527-4714
Szabo, Gyongyi
Abdelmalek, Manal F.
Byrne, Christopher D. http://orcid.org/0000-0001-6322-7753
Cusi, Kenneth
Dufour, Jean-François http://orcid.org/0000-0002-8062-1346
Roden, Michael
Sacks, Frank
Tacke, Frank
Article History
Accepted: 2 September 2020
First Online: 22 October 2020
Competing interests
: S.F. has a senior clinical research mandate from the Fund for Scientific Research (FWO) Flanders (1802154N) and has acted as advisor and/or lecturer for Roche, Gilead, Abbvie, Bayer, BMS, MSD, Janssen, Actelion, Astellas, Genfit, Inventiva, Intercept, Genentech and Galmed. G.S. has received research support from NIAAA (NIH), Gilead, Intercept, Allergan, Genfit, Novartis, SignaBlock, Shire, the University of Florida, BMS, Genentech, Takeda, and Vertex. She is a consultant/advisory board member for Allergan, Arrow Diagnostics, Pandion Therapeutics, Glympse Bio, Quest Diagnostic, Surrozen, Innovate Biopharmaceuticals, Alnylam, Zomagen, Novartis, Durect, Generon and Terrafirma. She is an author for UptoDate, editor for the American Association for the Study of Liver Diseases and Editor-in-Chief of <i>Hepatology Communications</i>. M.F.A. is supported by the National Institute of Health (NIH)/NIDDK Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN, U01DK061713, PI: A.M. Diehl) and is an advisor/consultant for Bristol Myers Squibb, NGM Pharma, Inventiva, Taiwan J, Immuron, Prometheus, and Novo-Nordisk. Her institution receives funding for research from NIH/NIDDK, Inventiva, Enyo, Enanta, Allergan, Novartis, Genfit, Intercept, BMS, NGM Parma, Gilead, Conatus, Durect, Poxel, Madrigal, Celgene, Galactin, Galmed, Novo-Nordisk, Taiwan J, Prometheus, TARGET NASH, and Progenity. She serves on speaker’s bureau for Simply Speaking NASH, iHEP NASH, PRIME NASH Programming, Clinical Care Options, and Alexion. C.D.B. is supported by the National Institute for Health Research (NIHR) through the NIHR Southampton Biomedical Research Centre. He is a consultant for Inventiva. K.C. has received research support for the University of Florida as principal investigator from the NIH, Cirius, Echosens, Inventiva, Novartis, Novo Nordisk, Poxel, TARGET NASH and Zydus. He is a consultant for Allergan, Astra-Zeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Genentech, Gilead, Janssen, Merck, Pfizer, Poxel, Prosciento, Novo Nordisk, Sanofi-Aventis, and TARGET NASH. J.-F.D. is a consultant/advisory board member for Abbvie, Allergan, Bayer, Bristol-Myers Squibb, Falk, Genfit, Genkyotex, Gilead Science, HepaRegenix, Intercept Pharma, Lilly, Merck, and Novartis. He serves as an investigator of studies supported by Abbvie, Bayer, BMS, Falk, Genfit, Gilead Science, Intercept, Inventiva, Lilly, Merck, and Novartis. M.R. has received research support from the Ministry of Culture and Science of the State of North Rhine-Westphalia and the German Federal Ministry of Health, grants from the European Fonds for Regional Development (EFRE-0400191), German Research Foundation (DFG, SFB 1116/2) and the Schmutzler Stiftung, serves as investigator of studies supported by Boehringer-Ingelheim Pharma, Nutricia/Danone, and Sanofi, and was advisor/consultant for Bristol-Myers Squibb, Eli Lilly, Gilead, Intercept Pharma, Novo Nordisk, Novartis, Poxel, Prosciento, Sanofi, Servier, and TARGET NASH. F.S. is a consultant to Pfizer, AstraZeneca, and Abbvie. F.T. has received research funding at Charité University Medicine Berlin from Allergan, Bristol-Myers Squibb, Galapagos, and Inventiva. He is a consultant for Allergan, Bayer, Boehringer Ingelheim, Galapagos, Galmed, Intercept, Inventiva, and Pfizer.